Digital Health Therapies for Chronic Insomnia

This policy addresses digital health therapies for chronic insomnia, including prescription CBT‑I software Somryst® (FDA 510(k) cleared) and internet‑delivered CBT‑I programs (eg, SHUTi). These interventions are intended for adults with chronic insomnia (Somryst indicated for ≥22 years; many trials enrolled adults ≥18 with ISI ≥12), but the policy cites limited direct RCT evidence for Somryst, high trial attrition, and major limitations/requirements—therapies are considered experimental/investigational and not covered, Somryst requires a prescriber order and compatible devices, coverage is governed by the member’s benefit plan, and this medical policy is currently inactive.

"Insomnia characterized by difficulty initiating and/or maintaining sleep with associated daytime impairment (malaise, fatigue, memory/concentration difficulties, and/or mood disturbances)."